Imunon (IMNN) Common Equity (2010 - 2026)
Imunon's (IMNN) quarterly Common Equity came in at $3.4 million in Q1 2026, up 643.24% YoY from $452028.0 in Q1 2025, and down 52.99% on a QoQ basis from $7.1 million in Q4 2025.
Imunon (IMNN) Common Equity (2010 - 2026) Analysis & Trends
Imunon (IMNN) has 17 years of Common Equity data on file, last reported at $3.4 million in Q1 2026.
- Quarterly Common Equity rose 643.24% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 643.24% YoY) and the FY2025 annual result came in at $7.1 million, up 68.39% from the prior year.
- Common Equity eased to $3.4 million in Q1 2026, from $7.1 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $47.0 million in Q2 2022 to a low of $452028.0 in Q1 2025.
- A 5-year average of $16.8 million and a median of $8.5 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity plunged 94.68% — and 2026, when it jumped 643.24%.
- Tracing IMNN's Common Equity over 5 years: stood at $29.3 million in 2022, then sank by 54.35% to $13.4 million in 2023, then tumbled by 68.3% to $4.2 million in 2024, then soared by 68.39% to $7.1 million in 2025, then tumbled by 52.99% to $3.4 million in 2026.
- The last three Common Equity figures came in at $3.4 million (Q1 2026), $7.1 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 9.79 Bn |
| 10 | Imunon | 8.60 Mn | 8.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.36 Mn |
| Dec 31, 2025 | 7.15 Mn |
| Sep 30, 2025 | 4.08 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Mar 31, 2025 | 452,028.00 |
| Dec 31, 2024 | 4.24 Mn |
| Sep 30, 2024 | 8.19 Mn |
| Jun 30, 2024 | 3.74 Mn |
| Mar 31, 2024 | 8.50 Mn |
| Dec 31, 2023 | 13.39 Mn |
| Sep 30, 2023 | 18.16 Mn |
| Jun 30, 2023 | 21.52 Mn |
| Mar 31, 2023 | 26.65 Mn |
| Dec 31, 2022 | 29.33 Mn |
| Sep 30, 2022 | 41.35 Mn |
| Jun 30, 2022 | 47.04 Mn |
| Mar 31, 2022 | 46.27 Mn |
| Dec 31, 2021 | 55.80 Mn |
| Sep 30, 2021 | 59.34 Mn |
| Jun 30, 2021 | 64.05 Mn |